Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer

M. Ponz De Leon, P. Benatti, C. Di Gregorio, M. Pedroni, L. Losi, M. Genuardi, A. Viel, M. Fornasarig, E. Lucci-Cordisco, M. Anti, G. Ponti, F. Borghi, I. Lamberti, L. Roncucci

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) is frequently associated with constitutional mutations in a class of genes involved in DNA mismatch repair. We identified 32 kindreds, with germline mutations in one of three genes hMSH2, hMLH1 or hMSH6. In this study, we purposed to evaluate how many high-risk individuals in each family underwent genetic testing: moreover, we assessed how many mutation-positive unaffected individuals accepted colonoscopic surveillance and the main findings of the recommended follow-up. Families were identified through a population-based registry, or referred from other centres. Members of the families were invited for an education session with two members of the staff When a kindred was consistent with HNPCC, neoplastic tissues were examined for microsatellite instability (MSI) and immunohistochemical expression of MSH2, MLH1 and MSH6 proteins. Moreover, constitutional mutations were searched by SSCP or direct sequencing of the whole genomic region. Of the 164 subjects assessed by genetic testing, 89 were gene carriers (66 affected - that is, with HNPCC-related cancer diagnosis - and 23 unaffected) and 75 tested negative. Among the 23 unaffected gene carriers, 18 (78.3%) underwent colonoscopy and four declined. On a total of 292 first degree at risk of cancer, 194 (66.4%) did not undergo genetic testing. The main reasons for this were: (a) difficulty to reach family members at risk, (b) lack of collaboration, (c) lack of interest in preventive medicine or 'fatalistic' attitude towards cancer occurrence. The number of colorectal lesions detected at endoscopy in gene carriers was significantly (P <0.01) higher than in controls (noncarriers). We conclude that a large fraction of high-risk individuals in mutation-positive HNPCC families does not undergo genetic testing, despite the benefits of molecular screening and endoscopic surveillance. This clearly indicates that there are still barriers to genetic testing in HNPCC, and that we are unable to provide adequate protection against cancer development in these families.

Original languageEnglish
Pages (from-to)882-887
Number of pages6
JournalBritish Journal of Cancer
Volume90
Issue number4
DOIs
Publication statusPublished - Feb 23 2004

Fingerprint

Hereditary Nonpolyposis Colorectal Neoplasms
Genetic Testing
Mutation
Genes
Neoplasms
Single-Stranded Conformational Polymorphism
Microsatellite Instability
Preventive Medicine
DNA Mismatch Repair
Germ-Line Mutation
Colonoscopy
Endoscopy
Registries
Education
Population

Keywords

  • Cancer
  • Colon
  • HNPCC
  • MSI
  • Rectum
  • Tumour

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ponz De Leon, M., Benatti, P., Di Gregorio, C., Pedroni, M., Losi, L., Genuardi, M., ... Roncucci, L. (2004). Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer. British Journal of Cancer, 90(4), 882-887. https://doi.org/10.1038/sj.bjc.6601529

Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer. / Ponz De Leon, M.; Benatti, P.; Di Gregorio, C.; Pedroni, M.; Losi, L.; Genuardi, M.; Viel, A.; Fornasarig, M.; Lucci-Cordisco, E.; Anti, M.; Ponti, G.; Borghi, F.; Lamberti, I.; Roncucci, L.

In: British Journal of Cancer, Vol. 90, No. 4, 23.02.2004, p. 882-887.

Research output: Contribution to journalArticle

Ponz De Leon, M, Benatti, P, Di Gregorio, C, Pedroni, M, Losi, L, Genuardi, M, Viel, A, Fornasarig, M, Lucci-Cordisco, E, Anti, M, Ponti, G, Borghi, F, Lamberti, I & Roncucci, L 2004, 'Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer', British Journal of Cancer, vol. 90, no. 4, pp. 882-887. https://doi.org/10.1038/sj.bjc.6601529
Ponz De Leon M, Benatti P, Di Gregorio C, Pedroni M, Losi L, Genuardi M et al. Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer. British Journal of Cancer. 2004 Feb 23;90(4):882-887. https://doi.org/10.1038/sj.bjc.6601529
Ponz De Leon, M. ; Benatti, P. ; Di Gregorio, C. ; Pedroni, M. ; Losi, L. ; Genuardi, M. ; Viel, A. ; Fornasarig, M. ; Lucci-Cordisco, E. ; Anti, M. ; Ponti, G. ; Borghi, F. ; Lamberti, I. ; Roncucci, L. / Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer. In: British Journal of Cancer. 2004 ; Vol. 90, No. 4. pp. 882-887.
@article{b293b8663ef24a4db1bfb38f5849cd8a,
title = "Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer",
abstract = "Hereditary nonpolyposis colorectal cancer (HNPCC) is frequently associated with constitutional mutations in a class of genes involved in DNA mismatch repair. We identified 32 kindreds, with germline mutations in one of three genes hMSH2, hMLH1 or hMSH6. In this study, we purposed to evaluate how many high-risk individuals in each family underwent genetic testing: moreover, we assessed how many mutation-positive unaffected individuals accepted colonoscopic surveillance and the main findings of the recommended follow-up. Families were identified through a population-based registry, or referred from other centres. Members of the families were invited for an education session with two members of the staff When a kindred was consistent with HNPCC, neoplastic tissues were examined for microsatellite instability (MSI) and immunohistochemical expression of MSH2, MLH1 and MSH6 proteins. Moreover, constitutional mutations were searched by SSCP or direct sequencing of the whole genomic region. Of the 164 subjects assessed by genetic testing, 89 were gene carriers (66 affected - that is, with HNPCC-related cancer diagnosis - and 23 unaffected) and 75 tested negative. Among the 23 unaffected gene carriers, 18 (78.3{\%}) underwent colonoscopy and four declined. On a total of 292 first degree at risk of cancer, 194 (66.4{\%}) did not undergo genetic testing. The main reasons for this were: (a) difficulty to reach family members at risk, (b) lack of collaboration, (c) lack of interest in preventive medicine or 'fatalistic' attitude towards cancer occurrence. The number of colorectal lesions detected at endoscopy in gene carriers was significantly (P <0.01) higher than in controls (noncarriers). We conclude that a large fraction of high-risk individuals in mutation-positive HNPCC families does not undergo genetic testing, despite the benefits of molecular screening and endoscopic surveillance. This clearly indicates that there are still barriers to genetic testing in HNPCC, and that we are unable to provide adequate protection against cancer development in these families.",
keywords = "Cancer, Colon, HNPCC, MSI, Rectum, Tumour",
author = "{Ponz De Leon}, M. and P. Benatti and {Di Gregorio}, C. and M. Pedroni and L. Losi and M. Genuardi and A. Viel and M. Fornasarig and E. Lucci-Cordisco and M. Anti and G. Ponti and F. Borghi and I. Lamberti and L. Roncucci",
year = "2004",
month = "2",
day = "23",
doi = "10.1038/sj.bjc.6601529",
language = "English",
volume = "90",
pages = "882--887",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer

AU - Ponz De Leon, M.

AU - Benatti, P.

AU - Di Gregorio, C.

AU - Pedroni, M.

AU - Losi, L.

AU - Genuardi, M.

AU - Viel, A.

AU - Fornasarig, M.

AU - Lucci-Cordisco, E.

AU - Anti, M.

AU - Ponti, G.

AU - Borghi, F.

AU - Lamberti, I.

AU - Roncucci, L.

PY - 2004/2/23

Y1 - 2004/2/23

N2 - Hereditary nonpolyposis colorectal cancer (HNPCC) is frequently associated with constitutional mutations in a class of genes involved in DNA mismatch repair. We identified 32 kindreds, with germline mutations in one of three genes hMSH2, hMLH1 or hMSH6. In this study, we purposed to evaluate how many high-risk individuals in each family underwent genetic testing: moreover, we assessed how many mutation-positive unaffected individuals accepted colonoscopic surveillance and the main findings of the recommended follow-up. Families were identified through a population-based registry, or referred from other centres. Members of the families were invited for an education session with two members of the staff When a kindred was consistent with HNPCC, neoplastic tissues were examined for microsatellite instability (MSI) and immunohistochemical expression of MSH2, MLH1 and MSH6 proteins. Moreover, constitutional mutations were searched by SSCP or direct sequencing of the whole genomic region. Of the 164 subjects assessed by genetic testing, 89 were gene carriers (66 affected - that is, with HNPCC-related cancer diagnosis - and 23 unaffected) and 75 tested negative. Among the 23 unaffected gene carriers, 18 (78.3%) underwent colonoscopy and four declined. On a total of 292 first degree at risk of cancer, 194 (66.4%) did not undergo genetic testing. The main reasons for this were: (a) difficulty to reach family members at risk, (b) lack of collaboration, (c) lack of interest in preventive medicine or 'fatalistic' attitude towards cancer occurrence. The number of colorectal lesions detected at endoscopy in gene carriers was significantly (P <0.01) higher than in controls (noncarriers). We conclude that a large fraction of high-risk individuals in mutation-positive HNPCC families does not undergo genetic testing, despite the benefits of molecular screening and endoscopic surveillance. This clearly indicates that there are still barriers to genetic testing in HNPCC, and that we are unable to provide adequate protection against cancer development in these families.

AB - Hereditary nonpolyposis colorectal cancer (HNPCC) is frequently associated with constitutional mutations in a class of genes involved in DNA mismatch repair. We identified 32 kindreds, with germline mutations in one of three genes hMSH2, hMLH1 or hMSH6. In this study, we purposed to evaluate how many high-risk individuals in each family underwent genetic testing: moreover, we assessed how many mutation-positive unaffected individuals accepted colonoscopic surveillance and the main findings of the recommended follow-up. Families were identified through a population-based registry, or referred from other centres. Members of the families were invited for an education session with two members of the staff When a kindred was consistent with HNPCC, neoplastic tissues were examined for microsatellite instability (MSI) and immunohistochemical expression of MSH2, MLH1 and MSH6 proteins. Moreover, constitutional mutations were searched by SSCP or direct sequencing of the whole genomic region. Of the 164 subjects assessed by genetic testing, 89 were gene carriers (66 affected - that is, with HNPCC-related cancer diagnosis - and 23 unaffected) and 75 tested negative. Among the 23 unaffected gene carriers, 18 (78.3%) underwent colonoscopy and four declined. On a total of 292 first degree at risk of cancer, 194 (66.4%) did not undergo genetic testing. The main reasons for this were: (a) difficulty to reach family members at risk, (b) lack of collaboration, (c) lack of interest in preventive medicine or 'fatalistic' attitude towards cancer occurrence. The number of colorectal lesions detected at endoscopy in gene carriers was significantly (P <0.01) higher than in controls (noncarriers). We conclude that a large fraction of high-risk individuals in mutation-positive HNPCC families does not undergo genetic testing, despite the benefits of molecular screening and endoscopic surveillance. This clearly indicates that there are still barriers to genetic testing in HNPCC, and that we are unable to provide adequate protection against cancer development in these families.

KW - Cancer

KW - Colon

KW - HNPCC

KW - MSI

KW - Rectum

KW - Tumour

UR - http://www.scopus.com/inward/record.url?scp=1642416883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642416883&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601529

DO - 10.1038/sj.bjc.6601529

M3 - Article

VL - 90

SP - 882

EP - 887

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -